

Application No. 10/806,088

Reply to Office Action

*AMENDMENTS TO THE CLAIMS*RECEIVED  
CENTRAL FAX CENTER

FEB 22 2007

1. (Canceled) [A method for treating a cancer in a human, wherein the cancer is susceptible to treatment with gossypol, a physiologically acceptable salt of gossypol, gossypolone, a physiologically acceptable salt of gossypolone, or any combination thereof, which method comprises:

administering to said human an anti-cancer effective amount of at least one compound selected from the group consisting of gossypol, a physiologically acceptable salt of gossypol, gossypolone, and a physiologically acceptable salt of gossypolone, and a pharmaceutically acceptable carrier.]

2. (Canceled) [The method of claim 1, wherein said cancer is adrenal, ovarian, thyroid, testicular, pituitary, prostate, or breast cancer.]

3. (Canceled) [The method of claim 2, wherein said cancer is adrenal cancer.]

4. (Canceled) [The method of claim 1, wherein the blood concentration of said compound is 400-1000 ng/dl.]

5. (Canceled) [The method of claim 4, wherein said compound is gossypolone or a physiologically acceptable salt of gossypolone.]

6. (Canceled) [The method of claim 5, wherein said gossypolone or physiologically acceptable salt of gossypolone is administered orally, rectally or vaginally at a dose of 50-200 mg/d. ]

7. (Canceled) [The method of claim 5, wherein said gossypolone or physiologically acceptable salt of gossypolone is administered parenterally at a dose of 1-5 mg/kg/d. ]

8. (Pending – Fourth Amendment) A method for treating a cancer in a human, wherein the cancer is susceptible to treatment with gossypol, a [pharmaceutically]

Application No. 10/806,088

Reply to Office Action

physiologically acceptable salt of gossypol, or a combination thereof, which method comprises;

administering to said human a composition comprising an anti-cancer effective amount of at least one compound selected from the group consisting of gossypol and a physiologically acceptable salt thereof, [and] wherein the at least one compound is administered with a pharmaceutically acceptable carrier, and wherein the at least one compound exhibits an overall effect of rotating the plane of polarized light in the (-) direction.

9. (Pending - Never Amended) The method of claim 8, wherein said cancer is adrenal, ovarian, thyroid, testicular, pituitary, prostate, or breast cancer.

10. (Pending - Never Amended) The method of claim 8, wherein said cancer is adrenal cancer.

11. (Pending - Twice Amended) The method of claim 8, wherein the blood concentration of said compound is [400] 200-1000 ng/dl.

12. (Pending - Once Amended) The method of claim 8, wherein said compound is administered parenterally at a dose of 1-2 mg/d.

13. (Pending - Once Amended) The method of claim 8, wherein said compound is administered orally at a dose of 20-100 mg/d.

14. (Pending - Once Amended) The method of claim 8, wherein said compound is administered rectally at a dose of 40-140 mg/d.

15. (Canceled)

16. (Pending - Never Amended) The method of claim 8, wherein said cancer is a carcinoid tumor of neuroendocrine tissue located in the lung, pancreas, or gastrointestinal tract.

Application No. 10/806,088

Reply to Office Action

17.-37. (Canceled)

38. (Pending – New) The method of claim 8, wherein said cancer is ovarian cancer.

39. (Pending – New) The method of claim 8, wherein said cancer is thyroid cancer.

40. (Pending – New) The method of claim 8, wherein said cancer is testicular cancer.

41. (Pending – New) The method of claim 8, wherein said cancer is pituitary cancer.

42. (Pending – New) The method of claim 8, wherein said cancer is prostate cancer.

43. (Pending – New) The method of claim 8, wherein said cancer is breast cancer.